Publications
5900 Results
- Journal / Conference
- ASCO GI Cancers Symposium (January 8 - 10, 2026, San Francisco, CA); J Clin Oncol 44, TPS790(2026); DOI: 10.1200/JCO.2026.44.2_suppl.TPS790
- Year
- 2026
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S2408
S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula
- Journal / Conference
- JAMA Network Open. 2026 Apr 1;9(4):e264901. doi: 10.1001/jamanetworkopen.2026.4901.
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- 41961500
- PMC
- PMC13069458
- Study Number(s)
- S1714
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714
- Journal / Conference
- Blood Advances 2026 May 8:bloodadvances.2026019616. doi: 10.1182/bloodadvances.2026019616
- Year
- 2026
- Research Committee(s)
- Leukemia
- PMID
- 42101912
- Study Number(s)
- C10403
Long-Term Follow-up of an Intensive Pediatric Regimen for Adolescents/Young Adults with Ph-negative Acute Lymphoblastic Leukemia: 10-year Survival Following CALGB 10403 (Alliance)
- Journal / Conference
- Cancers (Basel). 2026 Jan 25;18(3):373. doi: 10.3390/cancers18030373.
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- 41681846
- PMC
- PMC12896856
- Study Number(s)
- CTSU/A221504
Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study
- Journal / Conference
- Journal for the ImmunoTherapy of Cancer 2026 Feb 11. 14:e012805. doi:10.1136/jitc-2025-012805.
- Year
- 2026
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- 41672597
- Study Number(s)
- S1609
DART/SWOG/NCI phase II anti- CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
- Journal / Conference
- Journal of Clinical Oncology. 2026 June 3 epub. DOI: 10.1200/JCO-25-01896
- Year
- 2026
- Research Committee(s)
- Lung
- PMID
- 42234933
- Study Number(s)
- LUNGMAP
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective from Lung-MAP Investigators
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); TIP TPS8669 poster
- Year
- 2026
- Research Committee(s)
- Lung
- Study Number(s)
- S1800E
Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)
- Journal / Conference
- New England Journal of Medicine. 2026 Mar 25; 394: 1155-1166. DOI: 10.1056/NEJMoa2507874.
- Year
- 2026
- Research Committee(s)
- Gastrointestinal
- PMID
- 41880612
- PMC
- PMC13020640
- Study Number(s)
- CTSU/A021502
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer
- Journal / Conference
- Endocrine-Related Cancer. 2026 Jan 24; 33: e250415. DOI: 10.1530/ERC-25-0415. Print 2026 Jan 1
- Year
- 2026
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID41524552
- Study Number(s)
- CTSU/A021602
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602)
- Journal / Conference
- Journal of Thoracic Oncology. 2026 Feb 24; 103650. DOI: 10.1016/j.jtho.2026.103650.
- Year
- 2026
- Research Committee(s)
- Lung
- PMID
- PMID41747891
- PMC
- PMC13095140